Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

A single dose of either 30 µg or 60 µg of nonadjuvanted respiratory syncytial virus prefusion F protein antigen boosts humoral immune responses in women of childbearing age. The investigational vaccine was well tolerated and had a safety profile similar to that of the widely used combined Tdap vacci...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases 2018-04, Vol.217 (10), p.1616-1625
Main Authors:	Beran, Jiři, Lickliter, Jason D, Schwarz, Tino F, Johnson, Casey, Chu, Laurence, Domachowske, Joseph B, Van Damme, Pierre, Withanage, Kanchanamala, Fissette, Laurence A, David, Marie-Pierre, Maleux, Koen, Schmidt, Alexander C, Picciolato, Marta, Dieussaert, Ilse
Format:	Article
Language:	eng
Subjects:	Adjuvants, Immunologic - pharmacology Adolescent Adult Antibodies, Bacterial - immunology Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology Diphtheria-Tetanus-Pertussis Vaccine - immunology Female Humans Immunogenicity, Vaccine - immunology Major and Brief Reports Middle Aged Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Vaccines - adverse effects Respiratory Syncytial Virus Vaccines - immunology Respiratory Syncytial Virus, Human - immunology Vaccination - methods Whooping Cough - immunology Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A single dose of either 30 µg or 60 µg of nonadjuvanted respiratory syncytial virus prefusion F protein antigen boosts humoral immune responses in women of childbearing age. The investigational vaccine was well tolerated and had a safety profile similar to that of the widely used combined Tdap vaccine. Abstract Background Respiratory syncytial virus (RSV) causes bronchiolitis and pneumonia in neonates and infants. RSV vaccination during pregnancy could boost preexisting neutralizing antibody titers, providing passive protection to newborns. Methods Two observer-blinded, controlled studies (RSV F-020 [clinical trials registration NCT02360475] and RSV F-024 [NCT02753413]) evaluated immunogenicity and safety of an investigational RSV vaccine in healthy, nonpregnant 18–45-year-old women. Both studies used a licensed adult formulation of combined tetanus toxoid-diphtheria toxoid-acellular pertussis (Tdap) vaccine as a control. RSV F-020 evaluated immunogenicity and safety: participants were randomized (1:1:1:1) to receive 1 dose of RSV–prefusion F protein (PreF) vaccine containing 30 µg or 60 µg of nonadjuvanted RSV-PreF, 60 µg of aluminum-adjuvanted RSV-PreF, or Tdap. RSV F-024 evaluated safety: participants were randomized 1:1 to receive 1 dose of 60 µg of nonadjuvanted RSV-PreF or Tdap. Results Both studies showed similar reactogenicity profiles for RSV-PreF and Tdap. No serious adverse events were considered vaccine related. In RSV F-020, geometric mean ratios of RSV-A neutralizing antibody levels at day 30 versus prevaccination were 3.1–3.9 in RSV-PreF recipients and 0.9 in controls. Palivizumab-competing antibody concentrations increased >14-fold in RSV-PreF recipients on day 30. RSV antibody titers waned after day 30 but remained well above baseline through day 90. Conclusions All formulations of RSV-PreF boosted preexisting immune responses in 18–45-year old women with comparable immunogenicity. The RSV-PreF safety profile was similar to that of Tdap vaccine.
ISSN:	0022-1899 1537-6613